• Angiotensin III: From RAAS Biology to Assay Design

  2026-08-18

  Angiotensin III is more than a downstream RAAS metabolite: its sequence, receptor profile, and assay context determine how biological responses should be interpreted. This guide connects A1043 characterization with the 2025 spike–receptor binding study to support better cardiovascular, neuroendocrine, and biochemical assay design.

• PKH26 Red Fluorescent Cell Linker Kit Guide

  2026-08-18

  The PKH26 Red Fluorescent Cell Linker Kit provides membrane lipid-region labeling for longitudinal cell tracing and proliferation-oriented assays. It is intended for intact-cell membrane applications in vitro and in vivo, not for intracellular targets or non-membrane-specific labeling.

• ERK Links IFNγ Signaling to Melanoma Cell Death

  2026-08-17

  Champhekar et al. identify ERK as a central mediator of interferon-gamma-induced melanoma cell death, connecting cytokine signaling to a stress response involving DR5 and NOXA. Their complementary chemical-genetic, CRISPR, transcriptomic, imaging, and apoptosis assays provide a framework for studying why melanoma cells differ in sensitivity to immune-mediated growth inhibition.

• TNF-alpha Recombinant Murine Protein in Apoptosis

  2026-08-17

  Use TNF-alpha recombinant murine protein as a controlled apoptosis and inflammation stimulus, then compare its receptor-driven effects with RNA Pol II degradation-dependent cell death. This workflow emphasizes dose planning, orthogonal readouts, protein handling, and controls that prevent cytokine activity from being confused with transcriptional stress.

• GLT-1, CB1-CREB, and TBI Cognitive Dysfunction

  2026-08-16

  A 2025 Biomolecules study identifies a mechanistic link between post-traumatic 2-AG elevation, CB1-CREB signaling, reduced astrocytic GLT-1, and neuronal excitotoxicity. In mice, CB1 blockade restored GLT-1 expression, reduced neuronal apoptosis, and improved behavioral measures of cognitive dysfunction after traumatic brain injury.

• Dasatinib Monohydrate in Tumor–Stroma Assays

  2026-08-15

  Dasatinib Monohydrate is a powerful probe for studying kinase-dependent signaling in heterogeneous tumor models. This article explains how matched gastric cancer assembloids can distinguish tumor-intrinsic drug activity from stromal modulation, while preserving the compound’s relevance to imatinib-resistant BCR-ABL inhibition.

• Orientia tsutsugamushi Modulates RIPK3, Not Necroptosis

  2026-08-14

  The reference study shows that Orientia tsutsugamushi lowers cellular RIPK3 levels and avoids triggering necroptosis, but it cannot block the pathway once RIPK3 and MLKL signaling is experimentally induced. This distinction separates pathogen-mediated adjustment of host protein abundance from direct inhibition of necroptotic execution and provides a framework for interpreting scrub typhus pathogenesis.

• MDM1, p53, and Chemoradiotherapy Sensitivity in CRC

  2026-08-14

  The 2025 Cancer Biology & Medicine study identifies MDM1 as a potential marker and mechanistic regulator of chemoradiotherapy response in colorectal cancer. Its experiments connect MDM1 overexpression to reduced YBX1 association with the TP53 promoter, increased p53 expression, and greater apoptosis after treatment, while suggesting apoptosis-directed combinations for MDM1-low tumors.

• Licoricidin Targets PI3K/AKT in Liver Cancer

  2026-08-13

  This February 2026 study evaluates licoricidin as an experimental intervention for hepatocellular carcinoma (HCC), combining cell-based assays with xenograft and metastasis models. The findings connect reduced tumor growth and dissemination with apoptosis, cell-cycle arrest, epithelial–mesenchymal transition changes, and suppression of PI3K/AKT signaling, while leaving direct molecular target validation for future work.

• HyperFluor 488 Goat Anti-Human IgG: Assay Strategy

  2026-08-13

  The HyperFluor 488 Goat Anti-Human IgG (H+L) Antibody provides a practical bridge between SARS-CoV-2 vaccine studies and sensitive human IgG detection. Learn how to distinguish binding-antibody signals from neutralization, select compatible assay formats, and design more reliable translational workflows.

• Fluorouracil Workflows for Solid-Tumor Research

  2026-08-12

  Build reproducible Fluorouracil and 5-Fluorouracil assays around mechanism, dose range, exposure time, and orthogonal validation. This guide connects HT-29 cytotoxicity benchmarks with SMC2/SMC4-informed breast cancer research while emphasizing practical troubleshooting and responsible interpretation.

• CCK8 Workflow for VSMC Proliferation Studies

  2026-08-12

  Build a reproducible cck8 workflow for measuring vascular smooth muscle cell proliferation, treatment response, and cytotoxicity. This guide translates findings on arachidonic acid metabolism and intimal hyperplasia into practical plate design, controls, optimization steps, and interpretation safeguards.

• Stable Yeast Expression of Exendin-4 for Diabetes

  2026-08-11

  Balius and colleagues developed recombinant Exendin-4 expression models in Escherichia coli and Saccharomyces cerevisiae, with chromosomal integration in yeast producing a protein signal at the expected size and confirming it by immunoassay. The study establishes a proof of concept for yeast-based Exendin-4 production, while leaving peptide yield, biological activity, purification, and oral delivery for future validation.

• Gasdermin C, Stemness, and Immune Evasion in PDAC

  2026-08-11

  A 2024 Advanced Science study identifies Gasdermin C (GSDMC) as a transcriptional regulator of pancreatic ductal adenocarcinoma stemness, metastasis, and immune evasion independent of pyroptosis. The work connects ADAM17-mediated cleavage and nuclear GSDMC localization with CXCL9-dependent immune remodeling, while showing that GSDMC targeting can improve responses to KRASG12D inhibition and PD-1 blockade.

• DMXAA (Vadimezan): Reliable Assay Design

  2026-08-10

  A scenario-driven guide to using DMXAA (Vadimezan), SKU A8233, in viability, proliferation, and cytotoxicity workflows. It connects mechanism, solvent handling, dose selection, interpretation, and vendor evaluation to more reproducible cancer biology research.

544 records 7/37 page Previous Next First page 上5页 678910 下5页 Last page